Loading clinical trials...
Loading clinical trials...
A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms With AZD8529 in Patients With Schizophrenia
The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.
Age
18 - 45 years
Sex
ALL
Healthy Volunteers
No
Research Site
Philadelphia, Pennsylvania, United States
Start Date
November 1, 2009
Primary Completion Date
October 1, 2011
Completion Date
October 1, 2011
Last Updated
November 1, 2011
59
ACTUAL participants
AZD8529
DRUG
Placebo to match AZD8529
DRUG
Lead Sponsor
AstraZeneca
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions